

PHARMACARE NEWSLETTER

October 27, 2003

03-008

Page 1 of 8

In this issue

Changes to Registration Desk Hours	1
PharmaCare - Acting Executive Directors' Roles	1
Special services fees	2
LCA CORRECTION NOTICE	2
Benefits	3
Non benefits	3
LCA updates	4
New drugs categorized to LCA and/or RDP	4
Limited coverage drugs	5
Drugs under review	7

This newsletter provides information on the PharmaCare program for British Columbia's community pharmacists. Please circulate among dispensing staff.

PharmaCare on the Web:

www.healthservices.gov.bc.ca/pharmic

Changes to Registration Desk Hours

Effective November 1, 2003, the hours of availability for the Fair PharmaCare Registration Desk will be:

8:00am to 8:00pm, Monday to Friday

8:00am to 4:00pm, Saturday and Sunday

Registration via the Web and IVR continue to be available outside these hours.

PharmaCare - Acting Executive Directors' Roles

PharmaCare currently has two Acting Executive Directors, Phyllis Chuly and Suzanne Solven. Phyllis is responsible for policy related to PharmaCare Plans (e.g. Fair PharmaCare, Plan B, etc.), the PharmaCare budget and the current Program Review. Suzanne is responsible for policy related to drug benefit decisions, the special authorization process and Federal/Provincial/Territorial initiatives related to the Common Drug Review, generic drug harmonization and best practices. Please forward inquiries to the appropriate A/Executive Director.



BRITISH
COLUMBIA

Ministry of Health Services

PHARMACARE NEWSLETTER

October 27, 2003

03-008

Page 2 of 8

Special services fees

The number of Special Services fees paid for by PharmaCare over the past months are

DATE	NO OF FEES	DATE	NO OF FEES
Mar 2003	2,901	Jul 2003	3,381
Apr 2003	3,145	Aug 2003	3,086
May 2003	2,941	Sept 2003	3,729
Jun 2003	3,183		

LCA CORRECTION NOTICE:

Please note the corrections to the new LCA/RDP Booklet, effective October 22, 2003:

DIN	MAN	DRUG NAME	CORRECTION	FULL OR PARTIAL	LCA PRICE
2059762	NVR	AREIDIA 30MG VIAL	Special Authority YES	P	\$106.979
2059789	NVR	AREIDIA 90MG VIAL	Special Authority YES	P	\$320.925
2177749	RPR	M-ESLON CAP 15MG	Changed from Partial to Full, as per PharmaCare claims	F	
2244550	MYP	PAMIDRONATE DISODIUM FOR INJ 3MG/ML	Special Authority YES	F	
2244552	MYP	PAMIDRONATE DISODIUM FOR INJ 9MG/ML	Special Authority YES	F	
2233999	RXP	RHOXAL-METFORMIN TAB 500MG	Drug Name correction	F	
2208245	PMS	PMS-SALBUTAMOL RESP SOL 0.5MG/ML	Addition to new booklet	F	
2208229	PMS	PMS-SALBUTAMOL RESP SOL 1MG/ML	Addition to new booklet	F	
2218984	RPH	RATIO-TERAZOSIN TAB 10MG	Addition to new booklet	F	

PHARMACARE NEWSLETTER

October 27, 2003

03-008

Page 3 of 8

Benefits

The following new products have been included as eligible PharmaCare benefits on Plans B, C, F, and I.

DIN	MAN	DRUG NAME	Short Term	Long Term	Plan G Eligible	Palliative Care Eligible
2246058	APX	Apo-Calcitonin Injectable Vial 200 IU/ml	N	Y	N	N
2245821	APX	Apo-Ketorolac 0.5% Ophthalmic Solution	Y	N	N	N
2247621	ODN	Chloral Hydrate-Odan Syrup 100mg/ml	Y	N	Y	Y
2248013	GPM	Gen-Paroxetine Tab 20mg	N	Y	Y	Y
2248014	GPM	Gen-Paroxetine Tab 30mg	N	Y	Y	Y
2091186	PMS	Pms-Salbutamol Oral Liquid 0.4mg/ml	N	Y	N	N
2247461	RPH	Ratio-Ketorolac 0.5% Ophthalmic Solution	Y	N	N	N
2247811	RPH	Ratio-Paroxetine Tab 20mg	N	Y	Y	Y
2247812	RPH	Ratio-Paroxetine Tab 30mg	N	Y	Y	Y
2247439	RXP	Rhoxal-Bisoprolol Tab 5mg	N	Y	N	Y
2247440	RXP	Rhoxal Bisoprolol Tab 10mg	N	Y	N	Y

Non benefits

PharmaCare recently completed the review of the following products and recommended that these products not be added as benefits under the program:

DIN	MAN	DRUG NAME
2248012	GPM	Gen-Paroxetine Tab 10mg
2247810	RPH	Ratio-Paroxetine Tab 10mg

PHARMACARE NEWSLETTER

October 27, 2003

03-008

Page 4 of 8

LCA updates

New drugs categorized to LCA and/or RDP

The following new products under the Low Cost Alternative Program (LCA) / Reference Drug Program (RDP) have been included as eligible PharmaCare benefits on Plans B, C, F, and I.

DIN	MAN	DRUG NAME	FULL/ PARTIAL	LCA/RDP Price	Short Term	Long Term	Plan G Eligible	Eligible for Palliative Care
2246194	APX	Apo-Amiodarone Tab 200mg	P	\$1 3334	N	Y	N	N
2248103	OBT	Co Simvastatin Tab 5mg	F		N	Y	N	N
2248104	OBT	Co Simvastatin Tab 10mg	F		N	Y	N	N
2248105	OBT	Co Simvastatin Tab 20mg	F		N	Y	N	N
2248106	OBT	Co Simvastatin Tab 40mg	F		N	Y	N	N
2248107	OBT	Co Simvastatin Tab 80mg	F		N	Y	N	N
2246699	APX	Apo-Naproxen EC Tab 250mg	P	\$0 2969	N	Y	N	Y
2246700	APX	Apo-Naproxen EC Tab 375mg	P	\$0 3842	N	Y	N	Y
2246701	APX	Apo-Naproxen EC Tab 500mg	P	\$0 7172	N	Y	N	Y
2246893	APX	Apo-Verap SR Tab 120mg	P	\$0 7187	N	Y	N	Y
2246894	APX	Apo-Verap SR Tab 180mg	P	\$0 8121	N	Y	N	Y
2246895	APX	Apo-Verap SR Tab 240mg	P	\$0 9019	N	Y	N	Y
2231542	PMS	Pms-Carbamazepine Chewtabs 100mg	P	\$0 0883	N	Y	Y	Y
2231540	PMS	Pms-Carbamazepine Chewtabs 200mg	P	\$0 1766	N	Y	Y	Y
2246897	PMS	*Pms-Lamotrigine Tab 25mg	F		N	Y	N	N
2246898	PMS	*Pms-Lamotrigine Tab 100mg	F		N	Y	N	N
2246899	PMS	*Pms-Lamotrigine Tab 150mg	P	\$1 4411	N	Y	N	N
2246629	PMS	Pms-Medroxyprogesterone Tab 10mg	P	\$0 3259	N	Y	N	N
2247655	PMS	Pms-Pravastatin Tab 10mg	P	\$0 9735	N	Y	N	N
2247656	PMS	Pms-Pravastatin Tab 20mg	P	\$1 1445	N	Y	N	N
2247657	PMS	Pms-Pravastatin Tab 40mg	P	\$1 3789	N	Y	N	N

PHARMACARE NEWSLETTER

October 27, 2003

03-008

Page 5 of 8

2247882	ODN	Proctol Suppositories	P	\$0 7907	N	Y	N	Y
2248008	RXP	Rhoxal-Glyburide Tab 2 5mg	P	\$0 0402	N	Y	N	Y
2248009	RXP	Rhoxal-Glyburide Tab 5mg	P	\$0 0667	N	Y	N	Y
2247875	RXP	Rhoxal-Metoprolol Tab 50mg	P	\$0 1250	N	Y	N	Y
2247876	RXP	Rhoxal-Metoprolol Tab 100mg	P	\$0 2247	N	Y	N	Y
2247856	RXP	Rhoxal-Pravastatin Tab 10mg	P	\$0 9735	N	Y	N	N
2247857	RXP	Rhoxal-Pravastatin Tab 20mg	P	\$1 1445	N	Y	N	N
2247858	RXP	Rhoxal-Pravastatin Tab 40mg	P	\$1 3789	N	Y	N	N

* Requires Special Authority

Limited coverage drugs

The following new products have been included as eligible *PharmaCare* benefits under the **Limited Coverage program on Plan Palliative Care and by special authority only** (please refer to Website for criteria).

DIN	MAN	Brand Name	Short Term	Long Term	Eligible for Palliative Care
2247933	APX	Apo-Carvedilol Tab 3 125mg	N	Y	Y
2247934	APX	Apo-Carvedilol Tab 6 25mg	N	Y	Y
2247935	APX	Apo-Carvedilol Tab 12 5mg	N	Y	Y
2247936	APX	Apo-Carvedilol Tab 25mg	N	Y	Y
2245914	PMS	Pms-Carvedilol Tab 3 125mg	N	Y	Y
2245915	PMS	Pms-Carvedilol Tab 6 25mg	N	Y	Y
2245916	PMS	Pms-Carvedilol Tab 12 5mg	N	Y	Y
2245917	PMS	Pms-Carvedilol Tab 25mg	N	Y	Y
2246967	RXP	*Rhoxal-Estradiol Derm 50	N	Y	N
2246968	RXP	*Rhoxal-Estradiol Derm 75	N	Y	N
2246969	RXP	*Rhoxal-Estradiol Derm 100	N	Y	N

*Requires Special Authority

PHARMACARE NEWSLETTER

October 27, 2003

03-008

Page 6 of 8

New LCA Categories

Please be advised that the following drugs will be included as New LCA Categories on PharmaNet, effective October 27, 2003:

New Category (Chemical Name)	DIN	MAN	Brand Name	LCA Status: Full / Partial	LCA Price
Bisoprolol Fumarate Tab 5mg	2247439	RXP	Rhoxal-Bisoprolol Tab 5mg	F	
	2241148	UNK	Monacor Tab 5mg	P	\$0.2543
Bisoprolol Fumarate Tab 10mg	2247440	RXP	Rhoxal Bisoprolol Tab 10mg	F	
	2241149	UNK	Monacor Tab 10mg	P	\$0.4214
Calcitonin	2246058	APX	Apo-Calcitonin Injectable 200 IU/ml	F	
	1926691	RPR	Calcimar Sol Inj 200 UI/ml	P	\$15.1378
*Carvedilol Tab 3.125mg	2247933	APX	Apo-Carvedilol Tab 3.125mg	F	
	2245914	PMS	Pms-Carvedilol Tab 3.125mg	F	
	2229650	GLA	Coreg (Carvedilol) Tab 3.125mg	P	\$0.9227
*Carvedilol Tab 6.25mg	2247934	APX	Apo-Carvedilol Tab 6.25mg	F	
	2245915	PMS	Pms-Carvedilol Tab 6.25mg	F	
	2229651	GLA	Coreg (Carvedilol) Tab 6.25mg	P	\$0.9227
*Carvedilol Tab 12.5mg	2247935	APX	Apo-Carvedilol Tab 12.5mg	F	
	2245916	PMS	Pms-Carvedilol Tab 12.5mg	F	
	2229652	GLA	Coreg (Carvedilol) Tab 12.5mg	P	\$0.9227
*Carvedilol Tab 25mg	2247936	APX	Apo-Carvedilol Tab 25mg	F	
	2245917	PMS	Pms-Carvedilol Tab 25mg	F	
	2229653	GLA	Coreg (Carvedilol) Tab 25mg	P	\$0.9227
Chloral Hydrate	792659	PMS	Pms-Chloral Hydrate Syrup	F	
	2247621	ODN	Chloral Hydrate-Odan Syrup 100mg/ml	P	\$0.0457

PHARMACARE NEWSLETTER

October 27, 2003

03-008

Page 7 of 8

Ketorolac Tromethamine	2245821	APX	Apo-Ketorolac 0.5% Ophthalmic Solution	F	
	2247461	RPH	Ratio-Ketorolac 0.5% Ophthalmic Solution	F	
	1968300	ALL	Acular Liquid 0.5%	P	\$2.3249
Paroxetine Hydrochloride Tab 20mg	2248013	GPM	Gen-Paroxetine Tab 20mg	F	
	2247811	RPH	Ratio-Paroxetine Tab 20mg	F	
	1940481	GLA	Paxil Tab 20mg	P	\$1.1521
Paroxetine Hydrochloride Tab 30mg	2248014	GPM	Gen-Paroxetine Tab 30mg	F	
	2247812	RPH	Ratio-Paroxetine Tab 30mg	F	
	1940473	GLA	Paxil Tab 30mg	P	\$1.2247
Salbutamol Sulphate 0.4mg/ml	2091186	PMS	Pms-Salbutamol Oral Liquid 0.4mg/ml	F	
	2212390	GLA	Ventolin Oral Liquid 0.4mg/ml	P	\$0.0565

* Requires Special Authority

Drugs under review

The following drug submissions are currently under review by the Drug Benefit Committee of PharmaCare:

alfuzosin (XATRAL [®] 10mg tabs), resubmission	methylphenidate hydrochloride (CONCERTA [®] tabs)
anakinra (KINERET [®] 150mg/ml Injection)	olanzapine (ZYPREXA [®] tabs), new indication
botulinum toxin (BOTOX [®] Injection), new indication	peginterferon alfa-2a (PEGASYS [®] 180mcg/0.5ml pre-filled syringes & 180mcg/1ml single use vials)
ciprofloxacin (CIPRO XL [®] 500mg modified release tabs)	perindopril erbumine/indapamide (BIPREL [®] 4mg/1.25mg tabs)
clopidogrel (PLAVIX [®] 75mg tabs), new indication	perindopril erbumine/indapamide (PRETERAX [®] 2mg/0.625mg tabs)
desmopressin (DDAVP [®] tabs), resubmission	pimecrolimus (ELIDEL [®] 1% cream)
desmopressin acetate (OCTOSTIM [®] 15mcg/ml injection)	pioglitazone (Actos [®] 15mg, 30mg and 45mg tabs), resubmission
donepezil (ARICEPT [®] 5mg and 10mg tabs), resubmission new data	risedronate sodium (ACTONEL [®] 5mg tabs), resubmission

PHARMACARE NEWSLETTER

October 27, 2003

03-008

Page 8 of 8

estradiol-17b (VAGIFEM [®] 25mcg vaginal tabs)	risperidone (RISPERDAL M-TAB [®] 0.5mg, 1mg and 2mg orally disintegrating tabs)
etanercept (ENBREL [®] injection), new indication	rivastigmine (EXELON [®] caps), resubmission
ezetimibe (EZETROL [®] 10mg tabs)	rofecoxib (VIOXX [®] 25mg tabs), new indication
fondaparinux sodium (ARIXTRATM 2.5mg injection), resubmission	rosuvastatin calcium (CRESTOR [®] 10mg, 20mg, and 40mg tabs)
galantamine (REMINYL [®] 4mg, 8mg and 12mg tabs), resubmission	rosiglitazone (AVANDIA [®] tabs), resubmission
ganciclovir (CYTOVENE [®] 500mg caps)	tacrolimus (PROTOPIC [®] 0.03% and 0.1% ointment), resubmission
glimepiride (AMARYL [®] 1mg, 2mg and 4mg tabs)	telithromycin (Ketek [®] 400mg tabs)
interferon beta - 1a (AVONEX [®] 30mcg once a week IM injectable), new indication	testosterone (ANDRODERM [®] 24.3mg transdermal delivery system)
irbesartan (AVAPRO [®] tabs), new indication	tiotropium bromide (SPIRIVA [®] 18 mcg caps)
latanoprost/timolol maleate (XALACOM [®] 50 mcg/ml ophthalmic solution)	trandolapril/verapamil hydrochloride SR (TARKA [®] 1/240mg, 2/180mg, 2/240mg & 4/240mg tabs)
levetiracetam (KEPPRA [®] 250mg, 500mg and 750mg tabs)	valdecoxib (BEXTRA [®] 10mg & 20mg tabs)
losartan (COZAAR [®] tabs), new indication	vitamin and mineral supplement (DIAPLEX)
methadone hydrochloride (METADOL [®] 1mg, 5mg, 10mg and 25mg tabs)	zoledronic acid (ZOMETA [®] 4mg vial)

